Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.
Hum Immunol. 2010 Dec;71(12):1180-6. doi: 10.1016/j.humimm.2010.09.011. Epub 2010 Sep 24.
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, and patients who are diagnosed with this tumor typically have a poor prognosis. The suppressive effects of CD4(+)FoxP3(+) regulatory T cells on antitumor immune response in HCC have been studied in great detail. CD8(+)FoxP3(+) regulatory T cells have recently been detected in tumors; however, the role of CD8(+)FoxP3(+) regulatory T cells in HCC is still unknown. Here, the frequency and phenotype of CD8(+)FoxP3(+) regulatory T cells were analyzed by multicolor flow cytometry in liver of HCC patients and healthy donors. We observed that the percentage of these cells in HCC patients was significantly higher than that observed in healthy control donors (p = 0.0155); their phenotype was close to that of CD4(+) regulatory T cells. Furthermore, we show that CD8(+)FoxP3(+) regulatory T cells are activated and act as effector memory cells (EM, CD45RA(-)CCR7(-)CD27(+/-)CD28(+)). Most importantly, a higher percentage of intrahepatic CD8(+)FoxP3(+) regulatory T cells was found in patients with advanced HCC than in those with early HCC in terms of tumor-node-metastasis (TNM) stage (stage I vs III, p = 0.0007). These data suggest that CD8(+)FoxP3(+) regulatory T cells may contribute to HCC immune escape and disease progression.
肝细胞癌(HCC)是最常见的原发性肝脏恶性肿瘤,被诊断为此类肿瘤的患者通常预后较差。CD4+FoxP3+调节性 T 细胞对 HCC 抗肿瘤免疫反应的抑制作用已被深入研究。最近在肿瘤中检测到 CD8+FoxP3+调节性 T 细胞,但 CD8+FoxP3+调节性 T 细胞在 HCC 中的作用尚不清楚。本研究采用多色流式细胞术分析 HCC 患者和健康供体肝组织中 CD8+FoxP3+调节性 T 细胞的频率和表型。结果显示,HCC 患者中这些细胞的比例明显高于健康对照组(p=0.0155);其表型与 CD4+调节性 T 细胞相似。此外,我们发现 CD8+FoxP3+调节性 T 细胞被激活,并作为效应记忆细胞(EM,CD45RA−CCR7−CD27+/-CD28+)发挥作用。最重要的是,与早期 HCC 患者相比,晚期 HCC 患者肝内 CD8+FoxP3+调节性 T 细胞的比例更高,按肿瘤-淋巴结-转移(TNM)分期,Ⅰ期与Ⅲ期相比(p=0.0007)。这些数据表明,CD8+FoxP3+调节性 T 细胞可能有助于 HCC 免疫逃逸和疾病进展。